

# Colorectal cancer prevention in ulcerative colitis: a case

Alimentary Pharmacology and Therapeutics

14, 145-153

DOI: [10.1046/j.1365-2036.2000.00698.x](https://doi.org/10.1046/j.1365-2036.2000.00698.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Medical therapies for ulcerative colitis and crohnâ€™s disease. Current Gastroenterology Reports, 2000, 2, 446-450.	1.1	15
2	Neoplastic and other complications of inflammatory bowel disease. Current Gastroenterology Reports, 2000, 2, 451-459.	1.1	6
3	Colorectal Cancer Complicating Ulcerative Colitis: A Review. American Journal of Gastroenterology, 2000, 95, 2710-2719.	0.2	94
4	Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology, 2001, 120, 1356-1362.	0.6	399
5	The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodiumâ€™-induced colitis. Gastroenterology, 2001, 121, 1407-1416.	0.6	99
6	Inflammation, carcinogenesis and cancer. International Immunopharmacology, 2001, 1, 1651-1667.	1.7	133
7	Relation between colitis and colon cancer. Lancet, The, 2001, 357, 246-247.	6.3	28
8	The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut, 2001, 48, 526-535.	6.1	2,433
9	Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. European Journal of Gastroenterology and Hepatology, 2001, 13, 1297-1301.	0.8	48
10	Diagnostic methodologies: serology, endoscopy, and radiology. Current Gastroenterology Reports, 2001, 3, 491-499.	1.1	3
11	5-amino-salicylate in the management of inflammatory bowel disease. Colorectal Disease, 2001, 3, 218-222.	0.7	8
12	Colorectal neoplasia in ulcerative colitis-recent advances. Histopathology, 2001, 39, 221-234.	1.6	71
13	Altered glycosylation in inflammatory bowel disease: a possible role in cancer development. Glycoconjugate Journal, 2001, 18, 851-858.	1.4	109
14	Colonic screening and surveillance. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2001, 15, 301-316.	1.0	6
15	Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. American Journal of Gastroenterology, 2001, 96, 2929-2933.	0.2	384
16	Does patient knowledge affect the colorectal cancer risk in ulcerative colitis?. Postgraduate Medical Journal, 2002, 78, 615-618.	0.9	9
17	Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut, 2002, 51, v10-v12.	6.1	337
18	Inflammatory Bowel Disease in Children and Adolescents: Working Group Report of the First World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. Journal of Pediatric Gastroenterology and Nutrition, 2002, 35, S151-S158.	0.9	16

#	ARTICLE	IF	CITATIONS
19	Strategische Konzepte bei Diagnostik und Therapie von Dysplasien bei chronisch entzündlichen Darmerkrankungen. <i>Visceral Medicine</i> , 2002, 18, 148-154.	0.5	0
20	Surveillance for colitis-associated cancer: we cannot stop now. <i>Digestive and Liver Disease</i> , 2002, 34, 319-321.	0.4	7
21	Cancer in inflammatory bowel disease. <i>Gastroenterology Clinics of North America</i> , 2002, 31, 237-254.	1.0	37
22	Role of Mesalazine in Acute and Long-Term Treatment of Ulcerative Colitis and Its Complications. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 42-47.	0.6	25
23	Ulcerative colitis. <i>Lancet, The</i> , 2002, 359, 331-340.	6.3	273
24	Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. <i>Trends in Molecular Medicine</i> , 2002, 8, 10-16.	3.5	281
25	Colorectal Cancer Surveillance for Patients with Inflammatory Bowel Disease. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2002, 12, 135-143.	0.6	9
26	Cancer prevention in patients with inflammatory bowel disease. <i>Gastroenterology Clinics of North America</i> , 2002, 31, 1133-1144.	1.0	34
27	Colorectal cancer in inflammatory bowel disease: molecular and clinical features. <i>Gastroenterology Clinics of North America</i> , 2002, 31, 551-564.	1.0	12
28	Which 5-ASA?. <i>Gut</i> , 2002, 51, 548-549.	6.1	8
29	Ulcerative Colitis and Colon Cancer: Strategies for Cancer Prevention. <i>Digestive Diseases</i> , 2002, 20, 38-48.	0.8	12
30	Cancer in inflammatory bowel disease. <i>Current Treatment Options in Gastroenterology</i> , 2002, 5, 163-171.	0.3	10
32	Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1889-1893.	1.9	30
33	Is your patient taking the medicine? A simple assay to measure compliance with 5-aminosalicylic acid-containing compounds. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 2053-2059.	1.9	10
34	Cancer Prevention in Inflammatory Bowel Disease and the Chemoprophylactic Potential of 5-Aminosalicylic Acid. <i>Inflammatory Bowel Diseases</i> , 2002, 8, 356-361.	0.9	62
35	Randomized Controlled Trial Comparing the Efficacy of a Video and Information Leaflet Versus Information Leaflet Alone on Patient Knowledge About Surveillance and Cancer Risk in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2002, 8, 407-412.	0.9	27
36	Chemoprevention of colorectal cancer in ulcerative colitis. <i>International Journal of Colorectal Disease</i> , 2003, 18, 392-400.	1.0	49
37	Surveillance colonoscopy for colitic cancer in inflammatory bowel disease. <i>Digestive Endoscopy</i> , 2003, 15, 256-262.	1.3	2

#	ARTICLE	IF	CITATIONS
38	Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 10-14.	1.9	97
39	Review article: the data supporting a role for aminosaliclates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 15-21.	1.9	101
40	Review article: colitis-associated cancer - time for new strategies. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 6-9.	1.9	20
41	Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 191-198.	1.9	226
42	Radical causes of cancer. <i>Nature Reviews Cancer</i> , 2003, 3, 276-285.	12.8	1,515
43	Colorectal cancer in inflammatory bowel disease: molecular and clinical features. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 525-537.	0.9	0
44	Colorectal cancer and high grade dysplasia complicating ulcerative colitis in Italy. <i>Digestive and Liver Disease</i> , 2003, 35, 628-634.	0.4	11
45	The color of dysplasia in ulcerative colitis. <i>Gastroenterology</i> , 2003, 124, 1135-1138.	0.6	44
46	Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. <i>Gastroenterology</i> , 2003, 125, 1576-1582.	0.6	219
47	Does The Use of 5-Aminosaliclates in Inflammatory Bowel Disease Prevent The Development of Colorectal Cancer?. <i>American Journal of Gastroenterology</i> , 2003, 98, 2784-2788.	0.2	102
48	Aminosaliclates and colorectal cancer in IBD: a not-so bitter pill to swallow. <i>American Journal of Gastroenterology</i> , 2003, 98, 1682-1687.	0.2	44
49	Epidermal Growth Factor for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2003, 349, 395-397.	13.9	27
50	Prevalence and management of inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 1275-1280.	0.8	93
51	Does Treatment of Inflammatory Bowel Disease Prevent Cancer?. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, S94-S96.	1.1	11
52	Does Monitoring Prevent Cancer in Inflammatory Bowel Disease?. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, S79-S83.	1.1	17
53	Screening for Colorectal Cancer. <i>Scandinavian Journal of Surgery</i> , 2003, 92, 20-24.	1.3	3
54	Medical management of ulcerative colitis. <i>British Journal of Hospital Medicine</i> , 2003, 64, 703-707.	0.3	1
55	Motion - Colonoscopic Surveillance is more Cost Effective than Colectomy in Patients with Ulcerative Colitis: Arguments Against the Motion. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2003, 17, 122-124.	1.8	5

#	ARTICLE	IF	CITATIONS
56	Motion - Colonoscopic Surveillance is More Cost Effective than Colectomy in Patients with Ulcerative Colitis: Arguments for the Motion. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2003, 17, 119-121.	1.8	1
57	Divergent patterns of total and cancer mortality in ulcerative colitis and Crohn's disease patients: the Florence IBD study 1978-2001. <i>Gut</i> , 2004, 53, 1309-1313.	6.1	68
58	Bowel Inflammation as Measured by Fecal Calprotectin. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 279-284.	1.1	189
59	CON: Surveillance for Ulcerative Colitis-Associated Cancer: Time to Change the Endoscopy and the Microscopy. <i>American Journal of Gastroenterology</i> , 2004, 99, 1633-1636.	0.2	12
60	Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee. <i>American Journal of Gastroenterology</i> , 2004, 99, 1371-1385.	0.2	1,021
61	Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 287-293.	1.9	205
62	Adenomatous colonic polyps are rare in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 879-887.	1.9	15
63	The chemoprevention of colorectal carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 31-35.	1.9	13
64	Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis - results from a randomized-controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 1353-1363.	1.9	28
65	Small Intestinal Adenocarcinoma in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 32-35.	0.9	95
66	Crohn's Is Not a 6-Week Disease. <i>Inflammatory Bowel Diseases</i> , 2004, 10, S2-S10.	0.9	30
67	Animal models of inflammatory bowel disease. <i>Journal of Pharmacological and Toxicological Methods</i> , 2004, 50, 81-92.	0.3	244
69	Chimioprévention du cancer colorectal dans les maladies inflammatoires intestinales chroniques. Quels sont les médicaments proposés ?. <i>Acta Endoscopica</i> , 2004, 34, 199-213.	0.0	0
70	Histoire naturelle et facteurs de risque du cancer colorectal au cours des maladies inflammatoires intestinales. <i>Acta Endoscopica</i> , 2004, 34, 231-236.	0.0	0
71	Epidemiology of IBD during the twentieth century: an integrated view. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 463-479.	1.0	142
72	Guidelines for the management of inflammatory bowel disease in adults. <i>Gut</i> , 2004, 53, v1-v16.	6.1	914
73	Future of capsule endoscopy. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2004, 14, 219-227.	0.6	36
75	Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. <i>Gastroenterology</i> , 2004, 126, 451-459.	0.6	1,134

#	ARTICLE	IF	CITATIONS
76	Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. <i>Gastroenterology</i> , 2004, 126, 1634-1648.	0.6	414
77	Ulcerative colitis with low-grade dysplasia. <i>Gastroenterology</i> , 2004, 127, 950-956.	0.6	39
78	Current therapy of ulcerative colitis in children. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 37-53.	0.9	10
79	Long-term risk of cancer in ulcerative colitis: A population-based cohort study from Copenhagen County. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 1088-1095.	2.4	281
80	IKK $\beta$ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer. <i>Cell</i> , 2004, 118, 285-296.	13.5	2,277
81	MANAGEMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE. <i>Acta Clinica Belgica</i> , 2004, 59, 304-314.	0.5	27
82	Colorectal cancer in inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2004, 20, 43-48.	1.0	28
83	Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. , 2004, , CD000279.		38
84	Update in Medical Therapy of Ulcerative Colitis. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, 557-569.	1.1	27
85	Colonoscopic surveillance in inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2005, 21, 585-588.	1.0	8
86	Endoscopic Factors in the Diagnosis of Colorectal Dysplasia in Chronic Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 428-434.	0.9	48
87	Consensus Conference: Colorectal Cancer Screening and Surveillance in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 314-321.	0.9	530
88	Optimizing Therapy in Patients with Pancolitis. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 937-946.	0.9	8
90	Practice Parameters for the Surgical Treatment of Ulcerative Colitis. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 1997-2009.	0.7	142
91	Données Épidémiologiques. <i>Acta Endoscopica</i> , 2005, 35, 751-752.	0.0	0
92	Proposal of a New Clinical Index Predictive of Endoscopic Severity in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2005, 50, 246-251.	1.1	20
93	Radical induction theory of ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2005, 11, 2371.	1.4	182
94	Advances in the Medical Treatment of Crohn's Disease. , 2005, , 59-92.		1

#	ARTICLE	IF	CITATIONS
95	Ulcerative colitis, colorectal cancer and colonoscopic surveillance. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 881-885.	0.6	10
96	Inflammation and Cancer: When NF- $\kappa$ B Amalgamates the Perilous Partnership. <i>Current Cancer Drug Targets</i> , 2005, 5, 325-344.	0.8	90
97	5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. <i>Gut</i> , 2005, 54, 1573-1578.	6.1	240
98	Will a 5-ASA a Day Keep the Cancer (and Dysplasia) Away?. <i>American Journal of Gastroenterology</i> , 2005, 100, 1354-1356.	0.2	45
99	Mesalamine promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 958-964.	0.6	34
100	Mesalazine Improves Replication Fidelity in Cultured Colorectal Cells. <i>Cancer Research</i> , 2005, 65, 3993-3997.	0.4	56
101	Preventing Neoplastic Progression in Ulcerative Colitis. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, S66-S69.	1.1	20
102	Increased Risk of Intestinal Cancer in Crohn's Disease: A Meta-Analysis of Population-Based Cohort Studies. <i>American Journal of Gastroenterology</i> , 2005, 100, 2724-2729.	0.2	500
103	The variable risk of colorectal cancer in patients with inflammatory bowel disease. <i>European Journal of Internal Medicine</i> , 2005, 16, 139-140.	1.0	2
104	5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: Can we afford to wait for "best evidence"? <i>Digestive and Liver Disease</i> , 2005, 37, 723-731.	0.4	22
105	Effect of 5-Aminosalicylate Use on Colorectal Cancer and Dysplasia Risk: A Systematic Review and Metaanalysis of Observational Studies. <i>American Journal of Gastroenterology</i> , 2005, 100, 1345-1353.	0.2	515
106	Natural History and Management of Flat and Polypoid Dysplasia in Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2006, 35, 573-579.	1.0	13
107	Colorectal Cancer Prognosis Among Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 335-342.	2.4	136
108	Histone Hyperacetylation Is Associated with Amelioration of Experimental Colitis in Mice. <i>Journal of Immunology</i> , 2006, 176, 5015-5022.	0.4	288
109	Incidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 760-765.	2.4	284
110	Colorectal Cancer Screening and Surveillance. <i>Surgical Oncology Clinics of North America</i> , 2006, 15, 1-20.	0.6	11
111	Surveillance for Cancer and Dysplasia in Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2006, 35, 581-604.	1.0	41
112	Cytokines, NF- $\kappa$ B, Microenvironment, Intestinal Inflammation and Cancer. <i>Cancer Treatment and Research</i> , 2006, 130, 67-87.	0.2	104

#	ARTICLE	IF	CITATIONS
113	Inflammation, a Key Event in Cancer Development. <i>Molecular Cancer Research</i> , 2006, 4, 221-233.	1.5	913
114	Chemoprevention for colon cancer: New opportunities, fact or fiction?. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 158-164.	0.6	14
115	Chemoprevention: Risk Reduction with Medical Therapy of Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2006, 35, 675-712.	1.0	39
116	Epidemiology and Risk Factors for Colorectal Dysplasia and Cancer in Ulcerative Colitis. <i>Gastroenterology Clinics of North America</i> , 2006, 35, 517-531.	1.0	108
117	Aminosalicylate Therapy in the Prevention of Dysplasia and Colorectal Cancer in Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 1346-1350.	2.4	117
118	Thirty-Year Analysis of a Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis. <i>Gastroenterology</i> , 2006, 130, 1030-1038.	0.6	611
119	Risk of Intestinal Cancer in Inflammatory Bowel Disease: A Population-Based Study From Olmsted County, Minnesota. <i>Gastroenterology</i> , 2006, 130, 1039-1046.	0.6	463
120	Predictive and Protective Factors Associated With Colorectal Cancer in Ulcerative Colitis: A Case-Control Study. <i>Gastroenterology</i> , 2006, 130, 1941-1949.	0.6	387
122	IBD: Cancer Risk and Surveillance. , 2006, , 45-49.		0
123	Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. , 2006, , CD000279.		168
124	ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. <i>Gastrointestinal Endoscopy</i> , 2006, 63, 558-565.	0.5	238
125	Is nuclear factor kappa-B the missing link between inflammation, cancer and alteration in hepatic drug metabolism in patients with cancer?. <i>European Journal of Cancer</i> , 2006, 42, 785-792.	1.3	33
126	5-Aminosalicylic acid enhances anchorage-independent colorectal cancer cell death. <i>European Journal of Cancer</i> , 2006, 42, 2609-2616.	1.3	23
127	The Approach to Dysplasia Surveillance in Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2006, 20, 251-253.	1.8	5
128	Surveillance Colonoscopy in Uc: Alternatives and Ways to Improve Outcome. , 0, , 15-17.		0
129	Do They Have a Role in Crohn's Disease?. , 0, , 25-27.		1
130	Factors affecting medication compliance in inflammatory bowel disease. <i>Gastrointestinal Nursing</i> , 2006, 4, 31-40.	0.0	8
132	Systematic review: adherence issues in the treatment of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 577-585.	1.9	261



#	ARTICLE	IF	CITATIONS
133	Systematic review: the use of mesalazine in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 841-855.	1.9	106
134	Review article: maintenance therapy in patients with ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 17-22.	1.9	32
135	Review article: indeterminate colitis – definition, diagnosis and management. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 13-17.	1.9	29
136	Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. <i>Cell Death and Differentiation</i> , 2006, 13, 202-211.	5.0	41
137	Risk factors for colorectal cancer in Crohn's colitis: A case-control study. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 491-496.	0.9	46
138	Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: Results of a population-based study. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 205-211.	0.9	188
139	Ulcerative colitis and clinical course: Results of a 5-year population-based follow-up study (the IBSSEN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.9	228
140	Colorectal cancer in inflammatory bowel disease: Molecular and clinical considerations. <i>Current Treatment Options in Gastroenterology</i> , 2006, 9, 211-220.	0.3	21
141	Neoplasia in inflammatory bowel disease: Surveillance and management strategies. <i>Current Gastroenterology Reports</i> , 2006, 8, 513-518.	1.1	12
142	Salicylate modulates oxidative stress in the rat colon: A proteomic approach. <i>Biochemical Pharmacology</i> , 2006, 72, 204-216.	2.0	27
143	Dietary administration with prenyloxycompounds, auraptene and collinin, inhibits colitis-related colon carcinogenesis in mice. <i>International Journal of Cancer</i> , 2006, 118, 2936-2942.	2.3	96
144	Ulcerative colitis: diagnosis and management. <i>BMJ: British Medical Journal</i> , 2006, 333, 340-343.	2.4	57
145	Optimizing management of distal ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 511-523.	0.6	4
146	Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/ $\beta$ -catenin pathway activity. <i>Carcinogenesis</i> , 2006, 27, 2371-2382.	1.3	79
147	Prevention of Colorectal Cancer in Inflammatory Bowel Disease: Value of Screening and 5-Aminosalicylates. <i>Digestion</i> , 2006, 73, 11-19.	1.2	42
148	Dysplasia and Cancer in Ulcerative Colitis: Too Many Questions, Too Few Answers. <i>Digestion</i> , 2006, 73, 9-10.	1.2	2
149	Distal adenomatous polyps are rare in patients with inflammatory bowel disease. <i>Postgraduate Medical Journal</i> , 2006, 82, 76-78.	0.9	9
150	Risk Factors for Colorectal Neoplasia in Inflammatory Bowel Disease: A Nested Case-Control Study From Copenhagen County, Denmark and Olmsted County, Minnesota. <i>American Journal of Gastroenterology</i> , 2007, 102, 829-836.	0.2	131

#	ARTICLE	IF	CITATIONS
151	State of the Art Reviews: Health Benefits Related to Exercise in Patients With Chronic Low-Grade Systemic Inflammation. <i>American Journal of Lifestyle Medicine</i> , 2007, 1, 289-298.	0.8	9
152	Colorectal Cancer: Epidemiology, Etiology, and Molecular Basis. , 2007, , 335-352.		0
153	Chemoprevention of Colorectal Cancer. <i>Digestion</i> , 2007, 76, 51-67.	1.2	72
154	Diagnosis and management of inflammatory bowel disease. <i>NursePrescribing</i> , 2007, 5, 289-296.	0.1	4
155	TLR4 signalling in the intestine in health and disease. <i>Biochemical Society Transactions</i> , 2007, 35, 1473-1478.	1.6	152
156	“Take Your Medicine” Gastroenterology Nursing, 2007, 30, 212-217.	0.2	8
157	Nonadherence With Thiopurine Immunomodulator and Mesalamine Medications in Children with Crohn Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2007, 44, 180-184.	0.9	54
159	Cancer and pediatric inflammatory bowel disease. <i>Seminars in Pediatric Surgery</i> , 2007, 16, 205-213.	0.5	22
160	The risks and the benefits of mesalazine as a treatment for ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2007, 6, 99-107.	1.0	43
161	Elective and Emergent Operative Management of Ulcerative Colitis. <i>Surgical Clinics of North America</i> , 2007, 87, 633-641.	0.5	26
162	Endoscopy/Surveillance in Inflammatory Bowel Disease. <i>Surgical Clinics of North America</i> , 2007, 87, 743-762.	0.5	20
163	Associated Neoplastic Disease in Inflammatory Bowel Disease. <i>Surgical Clinics of North America</i> , 2007, 87, 659-672.	0.5	9
164	5-ASA Affects Cell Cycle Progression in Colorectal Cells by Reversibly Activating a Replication Checkpoint. <i>Gastroenterology</i> , 2007, 132, 221-235.	0.6	69
165	Histologic Inflammation Is a Risk Factor for Progression to Colorectal Neoplasia in Ulcerative Colitis: A Cohort Study. <i>Gastroenterology</i> , 2007, 133, 1099-1105.	0.6	671
166	Increased Risk of Colorectal Cancer in Ulcerative Colitis Patients Diagnosed after 40 Years of Age. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , 2007, 21, 443-446.	1.8	37
167	Mild-to-Moderate Ulcerative Colitis: Your Role in Patient Compliance and Health Care Costs. <i>Journal of Managed Care Pharmacy</i> , 2007, 13, 2-15.	2.2	18
168	5-Aminosalicylic Acid Therapy and the Risk of Colorectal Cancer Among Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 367-371.	0.9	118
169	“How compliant do we want to be with the colonoscopy surveillance guidelines?” <i>Colorectal Disease</i> , 2007, 9, 830-833.	0.7	5

#	ARTICLE	IF	CITATIONS
170	Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action?. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1443-1449.	1.9	27
171	MMX Multi Matrix System mesalazine for the induction of remission in patients with mild to moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 205-215.	1.9	156
174	The Risk of Cancer in Patients with Crohn's Disease. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 839-855.	0.7	258
175	p53 codon 72 polymorphism in patients affected with ulcerative colitis. <i>Journal of Gastroenterology</i> , 2007, 42, 456-460.	2.3	16
176	Tumor-host interactions: the role of inflammation. <i>Histochemistry and Cell Biology</i> , 2008, 130, 1079-1090.	0.8	96
177	Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: A clinical review and update. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 265-274.	0.9	70
178	5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1341-1347.	0.9	58
179	Review article: improving adherence to medication in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 9-14.	1.9	58
180	Review article: evolving concepts in treatment and disease modification in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 15-21.	1.9	31
181	Review article: medication non-adherence in ulcerative colitis – strategies to improve adherence with mesalazine and other maintenance therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 1157-1166.	1.9	102
182	Cancer in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2008, 14, 378.	1.4	280
183	Improving Delivery of Aminosalicylates in Ulcerative Colitis. <i>Drugs</i> , 2008, 68, 1089-1103.	4.9	27
184	Strategies to Improve Adherence and Outcomes in Patients with Ulcerative Colitis. <i>Drugs</i> , 2008, 68, 2601-2609.	4.9	30
185	Chemoprevention of Colorectal Neoplasia: The Potential for Personalized Medicine. <i>Gastroenterology</i> , 2008, 134, 1224-1237.	0.6	103
186	The challenges of medication non-adherence in ulcerative colitis: Practical suggestions to help patients. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 97-98.	0.6	3
187	Inflammation: Gearing the journey to cancer. <i>Mutation Research - Reviews in Mutation Research</i> , 2008, 659, 15-30.	2.4	683
188	TLR4 signaling in cancer cells promotes chemoattraction of immature dendritic cells via autocrine CCL20. <i>Biochemical and Biophysical Research Communications</i> , 2008, 366, 852-856.	1.0	32
189	Progression to Colorectal Neoplasia in Ulcerative Colitis: Effect of Mesalamine. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1225-1230.	2.4	82

#	ARTICLE	IF	CITATIONS
190	Surveillance of Patients at Increased Risk of Colon Cancer: Inflammatory Bowel Disease and Other Conditions. <i>Gastroenterology Clinics of North America</i> , 2008, 37, 191-213.	1.0	18
191	High frequency of early colorectal cancer in inflammatory bowel disease. <i>Gut</i> , 2008, 57, 1246-1251.	6.1	173
192	Chemoprevention and screening in primary sclerosing cholangitis. <i>Postgraduate Medical Journal</i> , 2008, 84, 228-237.	0.9	24
193	PPAR $\alpha$ is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. <i>Carcinogenesis</i> , 2008, 29, 1407-1414.	1.3	57
194	Colon cancer surveillance in inflammatory bowel disease patients: current and emerging practices. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 817-825.	1.4	10
195	Citrus Compounds Inhibit Inflammation- and Obesity-Related Colon Carcinogenesis in Mice. <i>Nutrition and Cancer</i> , 2008, 60, 70-80.	0.9	50
196	Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase. <i>Carcinogenesis</i> , 2008, 29, 1258-1266.	1.3	30
197	Surveillance programmes for colorectal cancer in inflammatory bowel disease: have we got it right?. <i>Gut</i> , 2008, 57, 1194-1196.	6.1	6
198	DA-6034, a Derivative of Flavonoid, Prevents and Ameliorates Dextran Sulfate Sodium-Induced Colitis and Inhibits Colon Carcinogenesis. <i>Experimental Biology and Medicine</i> , 2008, 233, 180-191.	1.1	32
199	Balsalazide disodium for the treatment of ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2008, 2, 177-184.	1.4	14
200	Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial. <i>Patient Preference and Adherence</i> , 2008, 2, 253.	0.8	22
201	COLORECTAL CANCER IN ULCERATIVE COLITIS. , 2008, , 1509-1535.		0
202	The role of Asacol in the treatment of patients with ulcerative colitis. <i>Gastrointestinal Nursing</i> , 2008, 6, 8-14.	0.0	0
203	Colorectal Cancer in Inflammatory Bowel Disease. <i>Gut and Liver</i> , 2008, 2, 61-73.	1.4	77
204	Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies. <i>World Journal of Gastroenterology</i> , 2008, 14, 3937.	1.4	367
205	Colorectal cancer and dysplasia in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2008, 14, 2662.	1.4	129
206	Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease. <i>Clinical and Experimental Gastroenterology</i> , 2009, 2, 139.	1.0	5
207	Large Intestine (Colon). , 2009, , 755-836.		2

#	ARTICLE	IF	CITATIONS
208	Cost Effectiveness of Ulcerative Colitis Surveillance in the Setting of 5-Aminosalicylates. <i>American Journal of Gastroenterology</i> , 2009, 104, 2222-2232.	0.2	38
209	New approaches to adherence issues when dosing oral aminosalicylates in ulcerative colitis. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 451-457.	0.5	8
210	Colon cancer in inflammatory bowel disease: recent trends, questions and answers. <i>Gastroenterologie Clinique Et Biologique</i> , 2009, 33, S190-S201.	0.9	25
211	Co-prescribing azathiopurine or 6-mercaptopurine and 5-aminosalicylate compounds in ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 190-192.	0.9	6
212	Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 630-638.	0.9	124
213	Chemoprevention of Colonic Polyps with Balsalazide: An Exploratory, Double-Blind, Placebo-Controlled Study. <i>Digestive Diseases and Sciences</i> , 2009, 54, 2488-2496.	1.1	10
214	Inflammatory bowel disease and colorectal cancer: What is new?. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 35-39.	1.0	0
215	<i>In vivo</i> effects of mesalazine or <i>E. coli</i> Nissle 1917 on microsatellite instability in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 634-642.	1.9	8
216	Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. <i>British Journal of Cancer</i> , 2009, 101, 1671-1675.	2.9	141
217	Trends of ulcerative colitis-associated colorectal cancer in Korea: A KASID study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 667-671.	1.4	60
218	Emerging drugs for the treatment of ulcerative colitis. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 505-521.	1.0	24
219	Inhibition of cell proliferation and invasion in a human colon cancer cell line by 5-aminosalicylic acid. <i>Digestive and Liver Disease</i> , 2009, 41, 328-337.	0.4	13
220	Decreasing Time-Trends of Colorectal Cancer in a Large Cohort of Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2009, 136, 1561-1567.	0.6	227
221	Colon cancer: preventive agents and the present status of chemoprevention. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 211-219.	0.9	128
222	I219V Polymorphism in hMLH1 Gene in Patients Affected with Ulcerative Colitis. <i>Genetic Testing and Molecular Biomarkers</i> , 2009, 13, 193-197.	0.3	8
223	Nuclear Factor- $\kappa$ B Enhances ErbB2-Induced Mammary Tumorigenesis and Neoangiogenesis <i>In Vivo</i> . <i>American Journal of Pathology</i> , 2009, 174, 1910-1920.	1.9	45
224	Spermine Metabolism and Anticancer Therapy. <i>Current Cancer Drug Targets</i> , 2009, 9, 118-130.	0.8	48
225	Colorectal Cancer Complicating Inflammatory Bowel Disease. <i>Annals of Surgery</i> , 2010, 252, 330-335.	2.1	88

#	ARTICLE	IF	CITATIONS
227	Nrf2-Keap1 Signaling as a Potential Target for Chemoprevention of Inflammation-Associated Carcinogenesis. <i>Pharmaceutical Research</i> , 2010, 27, 999-1013.	1.7	153
228	Mesalamine Protects Against Colorectal Cancer in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1696-1703.	1.1	57
229	Do 5-ASAs prevent colorectal neoplasia in patients with ulcerative colitis? Still no answers. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 358-360.	0.9	4
230	Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1352-1356.	0.9	90
231	Oral 5-aminosalicylic acid therapy for mild-to-moderate ulcerative colitis. <i>Journal of the American Academy of Nurse Practitioners</i> , 2010, 22, 586-592.	1.4	2
232	Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies. <i>Therapeutic Advances in Chronic Disease</i> , 2010, 1, 107-114.	1.1	6
233	Dual Roles for Immunity in Gastrointestinal Cancers. <i>Journal of Clinical Oncology</i> , 2010, 28, 4045-4051.	0.8	214
234	DNA Methylation-Dependent Repression of PDZ-LIM Domain-Containing Protein 2 in Colon Cancer and Its Role as a Potential Therapeutic Target. <i>Cancer Research</i> , 2010, 70, 1766-1772.	0.4	45
235	Pros and Cons of Medical Management of Ulcerative Colitis. <i>Clinics in Colon and Rectal Surgery</i> , 2010, 23, 227-238.	0.5	9
236	Top-down therapy for IBD: rationale and requisite evidence. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 86-92.	8.2	97
237	Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee. <i>American Journal of Gastroenterology</i> , 2010, 105, 501-523.	0.2	1,080
238	AGA Technical Review on the Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2010, 138, 746-774.e4.	0.6	426
239	Inflammatory Bowel Disease Confers a Lower Risk of Colorectal Cancer to Females Than to Males. <i>Gastroenterology</i> , 2010, 138, 1697-1703.e2.	0.6	131
240	Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). <i>Gut</i> , 2010, 59, 666-689.	6.1	1,000
241	Chemoprophylaxis in colorectal cancer: current concepts and a practical algorithm for use. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, S57-S66.	1.9	1
242	Intestinal Inflammation and Cancer. <i>Gastroenterology</i> , 2011, 140, 1807-1816.e1.	0.6	917
243	Molecular Pathways Underlying IBD-Associated Colorectal Neoplasia: Therapeutic Implications [RETRACTED]. <i>American Journal of Gastroenterology</i> , 2011, 106, 719-730.	0.2	40
244	New Findings in the Diagnosis and Prevention of Colorectal Cancer in IBD. , 2011, , 265-280.		0

#	ARTICLE	IF	CITATIONS
245	Chemoprevention of colorectal cancer in inflammatory bowel disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 593-606.	1.0	31
246	Aminosalicylates. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 535-546.	1.0	32
247	Guidelines for the management of inflammatory bowel disease in adults. <i>Gut</i> , 2011, 60, 571-607.	6.1	1,127
248	Neoplasia in IBD. , 2011, , .		0
249	Increased Risk of Colorectal Cancer and Dysplasia in Patients With Crohn's Colitis and Primary Sclerosing Cholangitis. <i>Diseases of the Colon and Rectum</i> , 2011, 54, 1392-1397.	0.7	64
250	Risks and benefits of ileal pouchâ€“anal anastomosis for ulcerative colitis. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 83-99.	0.2	3
251	Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: a clinical practice survey nested in the CESAME cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 188-195.	1.9	55
252	Randomised clinical trial: the efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1088-1097.	1.9	29
254	Is Inflammatory Bowel Disease an Important Risk Factor Among Older Persons with Colorectal Cancer in the United States? A Population-Based Caseâ€“Control Study. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2378-2383.	1.1	24
255	Inflammatory bowel disease-associated colorectal cancer: proctocolectomy and mucosectomy do not necessarily eliminate pouch-related cancer incidences. <i>International Journal of Colorectal Disease</i> , 2011, 26, 533-552.	1.0	40
256	Immunohistochemical expression of CDX2, $\beta$ -catenin, and TP53 in inflammatory bowel disease-associated colorectal cancer. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 232-240.	0.9	25
257	Cancer surveillance strategies in ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1800-1813.	0.9	23
258	Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: Results from an exploratory randomized controlled trial. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1874-1881.	0.9	51
259	Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2011, 4, 237-248.	1.4	103
260	5-Aminosalicylate Is Not Chemoprophylactic for Colorectal Cancer in IBD: A Population Based Study. <i>American Journal of Gastroenterology</i> , 2011, 106, 731-736.	0.2	103
261	The Prevention of Colitis-Related Cancer by 5-Aminosalicylates: An Appealing Hypothesis that Remains Unproven. <i>American Journal of Gastroenterology</i> , 2011, 106, 737-740.	0.2	9
262	Role of 5-Aminosalicylate in Preventing Colorectal Cancer. <i>American Journal of Gastroenterology</i> , 2011, 106, 1720-1721.	0.2	2
263	The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the ss-catenin signaling pathway. <i>Carcinogenesis</i> , 2012, 33, 637-643.	1.3	36

#	ARTICLE	IF	CITATIONS
264	Potential avenues for immunotherapy of colitis-associated neoplasia. <i>Immunotherapy</i> , 2012, 4, 397-405.	1.0	5
265	Inflammation and cancer. <i>World Journal of Gastrointestinal Surgery</i> , 2012, 4, 62.	0.8	120
266	Conventional Medical Management of Ulcerative Colitis: Sulfasalazine and 5-Aminosalicylates. , 2012, , 453-466.		1
267	Surveillance Colonoscopy in Ulcerative Colitis: A Surgical Perspective. <i>Seminars in Colon and Rectal Surgery</i> , 2012, 23, 75-80.	0.2	0
268	Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. <i>Gut</i> , 2012, 61, 235-240.	6.1	132
269	Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and colorectal cancer. <i>Biological Reviews</i> , 2012, 87, 701-730.	4.7	122
270	The Role of Chemoprevention of Colorectal Cancer with 5-Aminosalicylates in Ulcerative Colitis. <i>Digestive Diseases</i> , 2012, 30, 55-59.	0.8	15
271	Colitis and Colorectal Cancer. <i>Digestive Diseases</i> , 2012, 30, 469-476.	0.8	26
272	5-Aminosalicylic Acid Is Not Protective Against Colorectal Cancer in Inflammatory Bowel Disease: A Meta-Analysis of Non-Referral Populations. <i>American Journal of Gastroenterology</i> , 2012, 107, 1298-1304.	0.2	91
273	Colorectal cancer in inflammatory bowel disease: What is the real magnitude of the risk?. <i>World Journal of Gastroenterology</i> , 2012, 18, 3839.	1.4	180
274	Colorectal Cancer in Ulcerative Colitis Patients. , 2012, , .		1
275	Ulcerative Colitis-Associated Colorectal Cancer Prevention by 5-Aminosalicylates: Current Status and Perspectives. , 0, , .		0
276	Risk of Colonic Neoplasia After Liver Transplantation for Primary Sclerosing Cholangitis. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 269-274.	0.9	42
277	Emerging avenues linking inflammation and cancer. <i>Free Radical Biology and Medicine</i> , 2012, 52, 2013-2037.	1.3	218
278	Acute sensitization of colon cancer cells to inflammatory cytokines by prophase arrest. <i>Biochemical Pharmacology</i> , 2012, 83, 1217-1228.	2.0	7
279	Outcome of Sporadic Adenomas and Adenoma-Like Dysplasia in Patients with Ulcerative Colitis Undergoing Polypectomy. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 226-235.	0.9	67
280	My Treatment Approach to the Management of Ulcerative Colitis. <i>Mayo Clinic Proceedings</i> , 2013, 88, 841-853.	1.4	3
281	Epidemiology and Disease Burden of Ulcerative Colitis in Taiwan: A Nationwide Population-Based Study. <i>Value in Health Regional Issues</i> , 2013, 2, 127-134.	0.5	9



#	ARTICLE	IF	CITATIONS
282	<scp>P</scp>ill<scp>C</scp>am colon capsule endoscopy <i>versus</i> conventional colonoscopy for the detection of severity and extent of ulcerative colitis. Journal of Digestive Diseases, 2013, 14, 117-124.	0.7	53
283	European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn's and Colitis, 2013, 7, 982-1018.	0.6	679
284	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. Journal of Crohn's and Colitis, 2013, 7, 1-33.	0.6	422
285	The Gut Microbiome Modulates Colon Tumorigenesis. MBio, 2013, 4, e00692-13.	1.8	582
286	Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Journal of Crohn's and Colitis, 2013, 7, 968-973.	0.6	45
287	Differential response of flat and polypoid colitis-associated colorectal neoplasias to chemopreventive agents and heterocyclic amines. Cancer Letters, 2013, 334, 62-68.	3.2	4
288	Dysplasia and colorectal cancer in a patient with ulcerative colitis and primary sclerosing cholangitis: A case report and a short review of the literature. Journal of Crohn's and Colitis, 2013, 7, e61-e65.	0.6	4
290	The Role of Anti-Inflammatory Drugs in Colorectal Cancer. Annual Review of Medicine, 2013, 64, 131-144.	5.0	108
291	The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPAR $\beta$ . Carcinogenesis, 2013, 34, 2580-2586.	1.3	30
292	Aneuploidy characterizes adjacent non-malignant mucosa of ulcerative colitis-associated but not sporadic colorectal carcinomas: a matched-pair analysis. Scandinavian Journal of Gastroenterology, 2013, 48, 679-687.	0.6	9
293	Colorectal neoplasia in long-standing ulcerative colitis " a prospective study from a low-prevalence area. Colorectal Disease, 2013, 15, e462-8.	0.7	12
294	5-Aminosalicylate is Not Protective From Neoplasia in Ulcerative Colitis. American Journal of Gastroenterology, 2013, 108, 1015.	0.2	5
295	"œDoctor, I Just Can"™t"œ. Inflammatory Bowel Diseases, 2013, 19, 540-541.	0.9	0
296	5-Aminosalicylic Acid and Chemoprevention: Does It Work?. Digestive Diseases, 2013, 31, 248-253.	0.8	23
299	5-Aminosalicylates Reduce the Risk of Colorectal Neoplasia in Patients with Ulcerative Colitis: An Updated Meta-Analysis. PLoS ONE, 2014, 9, e94208.	1.1	61
300	Novel Diagnostic and Therapeutic Techniques for Surveillance of Dysplasia in Patients with Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 361-370.	0.8	24
301	Ulcerative colitis: From inflammation to cancer. Do estrogen receptors have a role?. World Journal of Gastroenterology, 2014, 20, 11496.	1.4	31
302	Ulcerative colitis-associated colorectal cancer. World Journal of Gastroenterology, 2014, 20, 16389.	1.4	192

#	ARTICLE	IF	CITATIONS
303	Practice Parameters for the Surgical Treatment of Ulcerative Colitis. Diseases of the Colon and Rectum, 2014, 57, 5-22.	0.7	148
304	Advanced endoscopic imaging for surveillance for dysplasia and colorectal cancer in inflammatory bowel disease: Could the pathologist be further helped?. Saudi Journal of Gastroenterology, 2014, 20, 26.	0.5	6
305	Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: A case-control observational study based on registry data. International Journal of Cancer, 2014, 134, 189-196.	2.3	74
306	The Cancer "Fear" in IBD Patients: Is It Still REAL?. Journal of Gastrointestinal Surgery, 2014, 18, 213-218.	0.9	11
307	Spermine metabolism and radiation-derived reactive oxygen species for future therapeutic implications in cancer: an additive or adaptive response. Amino Acids, 2014, 46, 487-498.	1.2	15
308	The pan-cancer analysis of gene expression patterns in the context of inflammation. Molecular BioSystems, 2014, 10, 2270.	2.9	10
309	Importance of Nonpolypoid (Flat and Depressed) Colorectal Neoplasms in Screening for CRC in Patients with IBD. Gastrointestinal Endoscopy Clinics of North America, 2014, 24, 327-335.	0.6	19
310	Colitis-associated neoplasia: molecular basis and clinical translation. Cellular and Molecular Life Sciences, 2014, 71, 3523-3535.	2.4	49
311	Colorectal cancer in inflammatory bowel disease: Results of the 3rd ECCO pathogenesis scientific workshop (I). Journal of Crohn's and Colitis, 2014, 8, 5-18.	0.6	110
312	Should Patients With Inflammatory Bowel Disease Take Vitamin D to Prevent Cancer?. Clinical Gastroenterology and Hepatology, 2014, 12, 828-830.	2.4	4
313	Toward a Consensus on Endoscopic Surveillance of Patients with Colonic Inflammatory Bowel Disease. Gastrointestinal Endoscopy Clinics of North America, 2014, 24, 469-481.	0.6	21
314	Colorectal Cancer in Inflammatory Bowel Disease: Epidemiology, Pathogenesis and Surveillance. Gastrointestinal Tumors, 2014, 1, 146-154.	0.3	24
315	Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 2562-2569.	0.9	31
316	Colitis-associated colon cancer: Is it in your genes?. World Journal of Gastroenterology, 2015, 21, 11688.	1.4	48
317	Effect of curcumin on p38MAPK expression in DSS-induced murine ulcerative colitis. Genetics and Molecular Research, 2015, 14, 3450-3458.	0.3	26
318	Malignancies in inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2015, 50, 81-89.	0.6	14
319	Xylitol induces cell death in lung cancer A549 cells by autophagy. Biotechnology Letters, 2015, 37, 983-990.	1.1	13
320	Outcome of "indefinite for dysplasia" in inflammatory bowel disease: correlation with DNA flow cytometry and other risk factors of colorectal cancer. Human Pathology, 2015, 46, 939-947.	1.1	16

#	ARTICLE	IF	CITATIONS
321	The role of endoscopy in inflammatory bowel disease. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 1101-1121.e13.	0.5	287
322	Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2251-2263.	1.1	38
323	Thiopurine Therapy Reduces the Incidence of Colorectal Neoplasia in Patients with Ulcerative Colitis. Data from the ENEIDA Registry. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1063-1070.	0.6	45
325	Chemopreventive effects of standardized ethanol extract from the aerial parts of <i>Artemisia princeps</i> Pampanini cv. Sajabal via NF- $\kappa$ B inactivation on colitis-associated colon tumorigenesis in mice. <i>Food and Chemical Toxicology</i> , 2015, 75, 14-23.	1.8	12
326	Advanced gastrointestinal endoscopic imaging for inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2016, 22, 1246.	1.4	15
327	Identifying predictors of low adherence in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 503-507.	0.8	37
328	The continuing uncertainty about cancer risk in inflammatory bowel disease. <i>Gut</i> , 2016, 65, 889-893.	6.1	52
329	Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management. <i>Cancer Prevention Research</i> , 2016, 9, 887-894.	0.7	133
330	Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy. <i>Current Treatment Options in Gastroenterology</i> , 2016, 14, 507-534.	0.3	2
331	Risk factors for developing colorectal cancer in Japanese patients with ulcerative colitis: a retrospective observational studyâ€”CAPITAL (Cohort and Practice for IBD total management in) Tj ETQq1 1 0.784314 rgBT / Overlock	1.1	14
332	Clinical pattern and progression of ulcerative proctitis in the Japanese population: a retrospective study of incidence and risk factors influencing progression. <i>Colorectal Disease</i> , 2016, 18, O97-O102.	0.7	14
333	BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signalling. <i>Gut</i> , 2016, 65, 1151-1164.	6.1	40
334	Targeted Biopsies Identify Larger Proportions of Patients With Colonic Neoplasia Undergoing High-Definition Colonoscopy, Dye Chromoendoscopy, or Electronic Virtual Chromoendoscopy. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 704-712.e4.	2.4	65
335	Colorectal Cancer Screening in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2016, 61, 980-989.	1.1	27
336	Novel Hexosaminidase-Targeting Fluorescence Probe for Visualizing Human Colorectal Cancer. <i>Bioconjugate Chemistry</i> , 2016, 27, 973-981.	1.8	44
337	Acetamides: chemotherapeutic agents for inflammation-associated cancers. <i>Journal of Chemotherapy</i> , 2016, 28, 255-265.	0.7	35
338	Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 973-979.	2.4	56
340	Cancer Surveillance of Patients with Long-Standing Inflammatory Bowel Disease. , 2016, , 61-83.		0

#	ARTICLE	IF	CITATIONS
341	Chemoprevention of colorectal neoplasia. ANZ Journal of Surgery, 2017, 87, E228-E232.	0.3	7
342	IBD: Management of Dysplasia in Patients with Ulcerative Colitis. Difficult Decisions in Surgery: an Evidence-based Approach, 2017, , 83-96.	0.0	0
343	Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 1179-1192.	1.9	81
344	Chemoprevention of colorectal cancer in ulcerative colitis: digging deep in current evidence. Expert Review of Gastroenterology and Hepatology, 2017, 11, 339-347.	1.4	25
345	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. Journal of Crohn's and Colitis, 2017, 11, 649-670.	0.6	1,324
346	Sulfasalazine and 5-Aminosalicylates for Ulcerative Colitis. , 2017, , 389-397.		1
347	Incidence of Cancer and Screening in Inflammatory Bowel Disease. , 2017, , 639-652.		0
348	A Review of Compounds for Prevention of Colorectal Cancer. Current Pharmacology Reports, 2017, 3, 221-231.	1.5	5
349	Strategies for detecting colon cancer in patients with inflammatory bowel disease. The Cochrane Library, 2017, 9, CD000279.	1.5	37
350	Colonoscopy and Flexible Sigmoidoscopy in Colorectal Cancer Screening and Surveillance. Current Colorectal Cancer Reports, 2017, 13, 284-292.	1.0	0
351	Chemoprevention of Colorectal Cancer in High-Risk Patients: from Molecular Targets to Clinical Trials. Current Colorectal Cancer Reports, 2017, 13, 192-204.	1.0	0
352	Prevention of Colorectal Cancer in Inflammatory Bowel Disease Using Advanced Technologies. Clinical Gastroenterology, 2017, , 101-119.	0.0	0
353	Use and barriers to chromoendoscopy for dysplasia surveillance in inflammatory bowel disease. World Journal of Gastrointestinal Endoscopy, 2017, 9, 359.	0.4	8
354	Prevalence and Anatomic Distribution of Serrated and Adenomatous Lesions in Patients with Inflammatory Bowel Disease. Canadian Journal of Gastroenterology and Hepatology, 2017, 2017, 1-8.	0.8	43
355	Adherence in ulcerative colitis: an overview. Patient Preference and Adherence, 2017, Volume 11, 297-303.	0.8	41
356	Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis. Oncotarget, 2017, 8, 1031-1045.	0.8	80
357	Segmental Resection versus Total Proctocolectomy for Crohn's Colitis: What is the Best Operation in the Setting of Medically Refractory Disease or Dysplasia?. Inflammatory Bowel Diseases, 2018, 24, 532-538.	0.9	10
358	Dysplasia in Inflammatory Bowel Disease: Historical Review, Critical Histopathological Analysis, and Clinical Implications. Inflammatory Bowel Diseases, 2018, 24, 1895-1903.	0.9	14

#	ARTICLE	IF	CITATIONS
359	Chromoendoscopy for Dysplasia Surveillance in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1440-1452.	0.9	16
360	Colorectal dysplasia and adenocarcinoma in patients with ulcerative colitis: an experience from a tertiary care hospital. <i>World Journal of Surgical Oncology</i> , 2018, 16, 81.	0.8	1
361	A Novel Topical PPAR $\beta$ Agonist Induces PPAR $\beta$ Activity in Ulcerative Colitis Mucosa and Prevents and Reverses Inflammation in Induced Colitis Models. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 792-805.	0.9	20
362	European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal [Exit Strategies] in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 17-31.	0.6	151
363	A survey on the use of topical steroids in patients treated for lichen sclerosus-associated vulval squamous cell carcinoma. <i>Journal of Obstetrics and Gynaecology</i> , 2018, 38, 265-269.	0.4	5
364	Updates in colorectal cancer screening in inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2018, 34, 208-216.	1.0	12
365	Colorectal cancer prevention in patients with ulcerative colitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 103-109.	1.0	47
366	Dysplasia Surveillance in Inflammatory Bowel Disease. , 2019, , 435-445.e3.		0
367	Surveillance for colorectal cancer and chemoprevention in ulcerative and Crohn's colitis: The need for clinical strategies to increase effectiveness. <i>JGH Open</i> , 2019, 3, 370-373.	0.7	3
368	Biochemical Basis of Anti-Cancer-Effects of Phloretin—A Natural Dihydrochalcone. <i>Molecules</i> , 2019, 24, 278.	1.7	71
369	Asymptomatic Inflammatory Bowel Disease and Colorectal Cancer Screening Programs: How Common Is It and What Should be Done About It?. <i>Gastrointestinal Disorders</i> , 2019, 1, 261-265.	0.4	3
370	DNA flow cytometric and interobserver study of crypt cell atypia in inflammatory bowel disease. <i>Histopathology</i> , 2019, 75, 578-588.	1.6	24
371	Management of Inflammatory Bowel Disease-Associated Dysplasia in the Modern Era. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2019, 29, 531-548.	0.6	14
372	UC Surveillance. , 2019, , 155-167.		0
373	Risk of Early Colorectal Cancers Needs to Be Considered in Inflammatory Bowel Disease Care. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2273-2279.	1.1	6
374	Endoscopic detection and resection of dysplasia in inflammatory bowel disease-techniques with videos. <i>International Journal of Colorectal Disease</i> , 2019, 34, 569-580.	1.0	5
376	Early Surgery in Inflammatory Bowel Diseases Is a Better Option than Prolonged Conservative Treatment. <i>Visceral Medicine</i> , 2019, 35, 355-358.	0.5	2
377	Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 740-750.	1.1	19

#	ARTICLE	IF	CITATIONS
378	Utility of DNA Flow Cytometric Analysis of Paraffin-embedded Tissue in the Risk Stratification and Management of "Indefinite for dysplasia"™ in Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 472-481.	0.6	13
379	Tauroursodeoxycholic acid attenuates colitis-associated colon cancer by inhibiting nuclear factor kappaB signaling. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 544-551.	1.4	26
380	Family History Associates With Increased Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1807-1813.e1.	2.4	43
381	Endoscopic surveillance strategies for dysplasia in ulcerative colitis. <i>Frontline Gastroenterology</i> , 2020, 11, 124-132.	0.9	4
382	Nonconventional dysplasia in patients with inflammatory bowel disease and colorectal carcinoma: a multicenter clinicopathologic study. <i>Modern Pathology</i> , 2020, 33, 933-943.	2.9	44
383	Malignancies in Inflammatory Bowel Disease. <i>Digestion</i> , 2020, 101, 136-145.	1.2	48
384	Ulcerative colitis. <i>Nature Reviews Disease Primers</i> , 2020, 6, 74.	18.1	678
385	Endoscopic surveillance of colorectal cancer in inflammatory bowel diseases: a review of the literature. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 851-863.	1.1	7
386	Mesalazine Induces Oxidative Stress and Cytochrome c Release in Isolated Rat Heart Mitochondria: An Analysis of Cardiotoxic Effects. <i>International Journal of Toxicology</i> , 2020, 39, 241-247.	0.6	6
387	Revealing potential drug-disease-gene association patterns for precision medicine. <i>Scientometrics</i> , 2021, 126, 3723-3748.	1.6	4
388	5-Aminosalicylic acid inhibits stem cell function in human adenoma-derived cells: implications for chemoprophylaxis in colorectal tumorigenesis. <i>British Journal of Cancer</i> , 2021, 124, 1959-1969.	2.9	7
389	Non-conventional dysplastic subtypes in inflammatory bowel disease: a review of their diagnostic characteristics and potential clinical implications. <i>Journal of Pathology and Translational Medicine</i> , 2021, 55, 83-93.	0.4	13
390	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre cribado de displasia en pacientes con enfermedad inflamatoria intestinal. <i>Gastroenterología Y Hepatología</i> , 2021, 44, 435-447.	0.2	4
391	Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo) Tj ETQq1 1 0.784314 rgBT /Ove inflammatory bowel disease patients. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2021, 44, 435-447.	0.0	2
392	The Significance of Flat/Invisible Dysplasia and Nonconventional Dysplastic Subtypes in Inflammatory Bowel Disease: A Review of Their Morphologic, Clinicopathologic, and Molecular Characteristics. <i>Advances in Anatomic Pathology</i> , 2022, 29, 15-24.	2.4	13
393	pH-dependent vs. constant release of mesalazine in the treatment of ulcerative colitis: Do drug delivery concepts determine therapeutic efficacy? (Review). <i>Biomedical Reports</i> , 2021, 15, 96.	0.9	3
394	AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. <i>Gastroenterology</i> , 2021, 161, 1043-1051.e4.	0.6	102
395	5-Aminosalicylate Therapy. , 0, , 317-328.		1

#	ARTICLE	IF	CITATIONS
396	Inflammatory Bowel Disease: A Model of Chronic Inflammation-Induced Cancer. <i>Methods in Molecular Biology</i> , 2009, 511, 193-233.	0.4	36
397	Fatty Acid Mediators in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1259, 125-153.	0.8	9
398	Colorectal Cancer in Inflammatory Bowel Disease. , 2004, , 160-166.		2
401	Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 22, 1.	0.8	51
402	Functional Comparison between Genes Dysregulated in Ulcerative Colitis and Colorectal Carcinoma. <i>PLoS ONE</i> , 2013, 8, e71989.	1.1	6
403	Mechanistic roles of epithelial and immune cell signaling during the development of colitis-associated cancer. <i>Cancer Research Frontiers</i> , 2016, 2, 1-21.	0.2	24
404	The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders. <i>Current Neuropharmacology</i> , 2016, 14, 514-539.	1.4	43
405	A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. <i>Journal of Medicine and Life</i> , 2019, 12, 113-122.	0.4	354
406	Malignancy Associated with Inflammatory Bowel Disease. <i>Journal of the Korean Society of Coloproctology</i> , 2009, 25, 150.	0.2	5
407	Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. <i>World Journal of Gastroenterology</i> , 2008, 14, 3497.	1.4	87
408	Molecular basis of the potential of mesalazine to prevent colorectal cancer. <i>World Journal of Gastroenterology</i> , 2008, 14, 4434.	1.4	31
409	Colorectal cancer surveillance in inflammatory bowel disease: The search continues. <i>World Journal of Gastroenterology</i> , 2009, 15, 61.	1.4	62
410	5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2005, 11, 309.	1.4	56
411	Indications for 5-aminosalicylate in inflammatory bowel disease: Is the body of evidence complete. <i>World Journal of Gastroenterology</i> , 2006, 12, 6115.	1.4	37
412	Duration of treatment with 5-aminosalicylic acid compounds. <i>World Journal of Gastroenterology</i> , 2007, 13, 4310.	1.4	12
413	Understanding of chemoprophylaxis and concordance in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2010, 16, 578.	1.4	6
414	Thiopurines related malignancies in inflammatory bowel disease: Local experience in Granada, Spain. <i>World Journal of Gastroenterology</i> , 2013, 19, 4877.	1.4	16
415	From the surface to the single cell: Novel endoscopic approaches in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 11260.	1.4	17

#	ARTICLE	IF	CITATIONS
416	Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease?. <i>World Journal of Gastroenterology</i> , 2016, 22, 3679.	1.4	32
417	Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments. <i>World Journal of Gastroenterology</i> , 2019, 25, 4148-4157.	1.4	109
418	Colorectal cancer surveillance in patients with inflammatory bowel disease: What is new?. <i>World Journal of Gastrointestinal Endoscopy</i> , 2012, 4, 108.	0.4	24
419	Colorectal cancer surveillance in inflammatory bowel disease: A critical analysis. <i>World Journal of Gastrointestinal Endoscopy</i> , 2014, 6, 541.	0.4	10
420	A pilot study on the endoscopic surveillance of colorectal dysplasia and cancer in long-standing ulcerative colitis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2005, 97, 16-23.	0.1	4
421	Chemoprevention of Gastrointestinal Cancer: The Reality and the Dream. <i>Gut and Liver</i> , 2013, 7, 137-149.	1.4	13
422	Colorectal Dysplasia in Chronic Inflammatory Bowel Disease: Pathology, Clinical Implications, and Pathogenesis. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 876-895.	1.2	79
423	Colon Cancer Screening and Surveillance in Inflammatory Bowel Disease. <i>Clinical Endoscopy</i> , 2014, 47, 509.	0.6	37
424	A Systematic Review and Meta-Analysis on the Association between Inflammatory Bowel Disease Family History and Colorectal Cancer. <i>Gastroenterology Research and Practice</i> , 2021, 2021, 1-15.	0.7	5
425	Pharmacological Development of Aminosalicylates for the Treatment of Inflammatory Bowel Disease. , 2001, , 227-234.		0
426	Inflammatory Diseases of the Colon, Rectum, Anus and Perianal Region. , 2003, , 335-398.		0
427	Bewährte und neue diagnostische Strategien zur Früherkennung intestinaler Dysplasien und Neoplasien. , 2003, , 65-73.		0
428	Entzündliche Erkrankungen des Dickdarms, Anorektums und Perianalbereichs. , 2003, , 347-416.		0
430	Molecular Targets of Mesalazine in Colorectal Cancer. <i>Current Cancer Therapy Reviews</i> , 2008, 4, 262-266.	0.2	0
431	Patients at risk for colorectal cancer in inflammatory bowel disease. , 2009, , 92-96.		0
432	Place des 5-ASA dans le traitement des maladies inflammatoires cryptogéniques de l'intestin. , 2009, , 79-84.		0
433	Prevention of cancer in inflammatory bowel disease and the potential chemopreventive effect of aminosalicylates. , 2009, , 55-66.		0
434	Cancer in inflammatory bowel disease: is there a chance for cancer prevention?. , 2009, , 97-106.		0



#	ARTICLE	IF	CITATIONS
435	Role of the Host Inflammatory Response in Colon Carcinoma Initiation, Progression and Liver Metastasis. Cancer Metastasis - Biology and Treatment, 2010, , 289-319.	0.1	3
437	Crohn Disease. , 2011, , 999-1000.		0
438	MICI et cancers de lâ€™intestin. , 2011, , 139-147.		1
439	Inflammatory Bowel Disease Associated Colorectal Neoplasia. , 2012, 01, 002.		0
440	Intestinal Host-Microbiome Interactions. , 0, , .		0
441	Malignant Tumors Arising in Inflammatory Bowel Disease. , 2013, , 531-545.		0
444	The Natural History of Ulcerative Colitis. , 2014, , 23-30.		0
446	Colorectal Adenocarcinoma and Inflammatory Bowel Disease: An Update and Review. Surgery Current Research, 2015, 05, .	0.1	0
447	Crohn Disease. , 2016, , 1231-1234.		0
448	Malignant Tumors Arising in Inflammatory Bowel Disease. , 2017, , 669-683.		0
449	Screening for Colon Cancer in Inflammatory Bowel Disease. , 2019, , 17-31.		0
450	Operative Therapie der Colitis ulcerosa und Pouchitis. , 2020, , 305-317.		0
451	Inflammatory Mediators: Potential Drug Targets in Cancer. , 2020, , 139-156.		0
452	CED-assoziierte kolorektale Karzinome: PrÃvention und Ãeberwachungsstrategien. , 2020, , 483-488.		0
454	Colitis: predicting outcomes â€™ who gets cancer?. , 0, , 77-83.		0
455	Can we prevent cancer using current drugs?. , 0, , 205-219.		0
456	Management of low-grade dysplasia in inflammatory bowel disease. , 0, , 220-225.		0
457	Malignant Tumors Arising in Inflammatory Bowel Disease. , 2008, , 611-630.		0

#	ARTICLE	IF	CITATIONS
458	Implications of dysplasia in the prevention of ulcerative colitis-associated colon cancer. , 0, , 145-150.		0
459	Chemopreventive effect of aminosalicylates. , 0, , 151-158.		0
460	Can we prevent inflammatory bowel disease-related colorectal cancer with 5-aminosalicylic acid, azathioprine, or 6-mercaptopurine? The clinical evidence. , 0, , 193-200.		0
462	Mesalazine and cell cycle progression. , 0, , 236-243.		0
464	Inflammatory bowel disease-related cancer “ just the same as sporadic? “ Pro. , 0, , 85-91.		0
466	Overcoming adherence issues in ulcerative colitis. Gastroenterology and Hepatology, 2007, 3, 795-9.	0.2	6
467	Current management of inflammatory bowel disease and colorectal cancer. Gastrointestinal Cancer Research: GCR, 2011, 4, 53-61.	0.8	93
469	Chemopreventive effects of 5-amino salicylic acids on inflammatory bowel disease-associated colonic cancer and colonic dysplasia: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2015, 8, 2212-8.	1.3	3
470	Chromoendoscopy and Dysplasia Surveillance in Inflammatory Bowel Disease: Past, Present, and Future. Gastroenterology and Hepatology, 2015, 11, 304-11.	0.2	5
471	Advances in the Diagnosis and Management of Colonic Dysplasia in Patients With Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2017, 13, 357-362.	0.2	4
472	Common and differential genetically pathways between ulcerative colitis and colon adenocarcinoma. Gastroenterology and Hepatology From Bed To Bench, 2017, 10, S93-S101.	0.6	4
473	Anticancer therapeutics: a brief account on wide refinements. American Journal of Cancer Research, 2020, 10, 3599-3621.	1.4	1
474	Incident Colorectal Cancer in Inflammatory Bowel Disease. Cancers, 2022, 14, 721.	1.7	5
475	Colorectal Cancer in Ulcerative Colitis: Surveillance. , 0, , 247-253.		1
476	Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Frontiers in Medicine, 2021, 8, 765474.	1.2	131
477	Secondary colon cancer in patients with ulcerative colitis: a systematic review and meta-analysis. Journal of Gastrointestinal Oncology, 2021, 12, 2882-2890.	0.6	5
478	Inflammatory bowel disease and carcinogenesis. Cancer and Metastasis Reviews, 2022, 41, 301-316.	2.7	24
481	Lipocalin 2 potentially contributes to tumorigenesis from colitis via IL-6/STAT3/NF- $\kappa$ B signaling pathway. Bioscience Reports, 2022, , .	1.1	9

#	ARTICLE	IF	CITATIONS
482	Characteristics of inflammatory bowel diseases in patients with concurrent immune-mediated inflammatory diseases. World Journal of Gastroenterology, 2022, 28, 2843-2853.	1.4	0
483	Cancer and cardiovascular disease: can understanding the mechanisms of cardiovascular injury guide us to optimise care in cancer survivors?. Ecancermedicalsience, 0, 16, .	0.6	4
484	Scoping Review of Acupuncture and Moxibustion in the Treatment of Inflammatory Bowel Disease. Gastrointestinal Disorders, 2023, 5, 102-111.	0.4	0
486	Risk Factors of Cancer in Paediatric-onset Inflammatory Bowel Disease in Denmark and Finland. Journal of Pediatric Gastroenterology and Nutrition, 0, Publish Ahead of Print, .	0.9	1